Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration

NCT ID: NCT07121127

Last Updated: 2025-08-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-07-07
• Study Completion Date: 2030-03-09

Brief Summary

This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN group and the control group. Throughout the study, both groups will take oral vitamin C and vitamin E supplements for a total of 28 days. Participants in the FSN group will receive four treatment sessions over two weeks. Both groups will be assessed at the end of the FSN treating period during the mid-study period, with ocular blood flow dynamics measured using OCTA, followed by a two-week follow-up. The primary outcome of this trial is the change in visual acuity from baseline to week 2, with secondary outcomes including visual field, visual function scale, macular thickness, central avascular zone area vascular density, and choroidal thickness.

Conditions

Age - Related Macular Degeneration (AMD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fu's subcutaneous needling group

Fu's subcutaneous needling group with oral Vitamin C and vitamin E supplements

Group Type: EXPERIMENTAL

FSN+Vitamin supplement

Intervention Type: COMBINATION_PRODUCT

Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements

Control group

oral Vitamin C and vitamin E supplements

Group Type: OTHER

Vitamin Supplements

Intervention Type: DRUG

oral Vitamin C and vitamin E supplements

Interventions

FSN+Vitamin supplement

Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements

Intervention Type: COMBINATION_PRODUCT

Vitamin Supplements

oral Vitamin C and vitamin E supplements

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

（ 1 ） Age between 50 and 85 years old with no gender restrictions （ 2 ） Meets the diagnostic criteria for dry age-related macular degeneration (AMD) as outlined in the 2023 Chinese Clinical Practice Guidelines for Age-Related Macular Degeneration （ 3 ） Both monocular and binocular cases of dry AMD are included. For patients with bilateral lesions the experimental group is based on the patient's preferred eye (if both eyes are preferred the average of the data collected from both eyes is included in the analysis) （ 4 ） Participants must voluntarily consent and sign an informed consent form and be willing to cooperate with follow-up visits.

Exclusion Criteria

（ 1 ） Serious eye diseases that significantly affect the condition of the fundus excluding dry macular degeneration including fundus lesions such as fundus hemorrhage and wet macular degeneration; or concomitant eye diseases requiring immediate treatment such as acute glaucoma; severe opacity of the refractive media such as mature cataracts （ 2 ） In distance vision testing the patient cannot discern the direction of the largest character at a distance of 1 meter from the distance vision chart （ 3 ） Participants who have undergone eye surgery within the past six months （ 4 ） Participants with non-ophthalmic conditions that may severely affect vision such as large-area cerebral infarction cerebral hemorrhage diabetes thyroid eye disease vitamin A deficiency or Sjögren's syndrome （ 5 ） Pregnant or lactating women （ 6 ） Participants with severe anemia renal failure acute phase of cardiovascular disease implanted cardiac pacemaker thrombocytopenia or other hematological conditions with a high risk of severe subcutaneous bleeding or requiring skin puncture （ 7 ） Participants who have taken medications or consumed foods that affect ocular blood supply within the past week such as caffeine atropine or other treatments for macular degeneration （ 8 ） Participants who require contact lenses.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhiming Yan

OTHER

Sponsor Role: lead

Responsible Party

Zhiming Yan

postgraduate of the Second Clinical College of Guangzhou University of Chinese Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jian Sun

Role: PRINCIPAL_INVESTIGATOR

Guangzhou University of Chinese Medicine - Department of Acupuncture and Rehabilitation Clinical Medicine

Central Contacts

Jian Sun M.D.

Role: CONTACT

sunj3610@163.com

13580504600

Ming Zhi Yan

Role: CONTACT

2369680940@qq.com

15817400383

Other Identifiers

ZF2025-237-01

Identifier Type: -

Identifier Source: org_study_id